115 related articles for article (PubMed ID: 9561057)
1. Contrast-enhanced magnetic resonance angiography in the coronary and peripheral arteries.
Saeed M; Wendland MF; Engelbrecht M; Sakuma H; Higgins CB
Acad Radiol; 1998 Apr; 5 Suppl 1():S108-12. PubMed ID: 9561057
[No Abstract] [Full Text] [Related]
2. Comparative studies on the efficacy of MRI contrast agents in MRA.
Weinmann HJ; Bauer H; Ebert W; Frenzel T; Radüchel B; Platzek J; Schmitt-Willich H
Acad Radiol; 2002 May; 9 Suppl 1():S135-6. PubMed ID: 12019849
[No Abstract] [Full Text] [Related]
3. Contrast-enhanced 3D-TOF MRA of peripheral vessels: intravascular versus extracellular MR contrast media.
Engelbrecht MR; Saeed M; Wendland MF; Canet E; Oksendal AN; Higgins CB
J Magn Reson Imaging; 1998; 8(3):616-21. PubMed ID: 9626876
[TBL] [Abstract][Full Text] [Related]
4. Use of intravascular contrast agents in MRI.
Bjørnerud A; Wendland MF; Johansson L; Ahlstrom HK; Higgins CB; Oksendal A
Acad Radiol; 1998 Apr; 5 Suppl 1():S223-5. PubMed ID: 9561086
[No Abstract] [Full Text] [Related]
5. Improvement of image quality of non-invasive coronary artery imaging with magnetic resonance by the use of the intravascular contrast agent Clariscan (NC100150 injection) in patients with coronary artery disease.
Klein C; Schalla S; Schnackenburg B; Bornstedt A; Hoffmann V; Fleck E; Nagel E
J Magn Reson Imaging; 2003 Jun; 17(6):656-62. PubMed ID: 12766894
[TBL] [Abstract][Full Text] [Related]
6. Ultrasmall superparamagnetic iron oxide to enhance MRA of the renal and coronary arteries: studies in human patients.
Stillman AE; Wilke N; Li D; Haacke M; McLachlan S
J Comput Assist Tomogr; 1996; 20(1):51-5. PubMed ID: 8576482
[TBL] [Abstract][Full Text] [Related]
7. Differences in predominant enhancement mechanisms of superparamagnetic iron oxide and ultrasmall superparamagnetic iron oxide for contrast-enhanced portal magnetic resonance angiography. Preliminary results of an animal study original investigation.
Knollmann FD; Böck JC; Rautenberg K; Beier J; Ebert W; Felix R
Invest Radiol; 1998 Sep; 33(9):637-43. PubMed ID: 9766048
[TBL] [Abstract][Full Text] [Related]
8. Gadolinium-enhanced off-resonance contrast angiography.
Edelman RR; Storey P; Dunkle E; Li W; Carrillo A; Vu A; Carroll TJ
Magn Reson Med; 2007 Mar; 57(3):475-84. PubMed ID: 17326177
[TBL] [Abstract][Full Text] [Related]
9. High-resolution magnetic resonance coronary angiography of the entire heart using a new blood-pool agent, NC100150 injection: comparison with invasive x-ray angiography in pigs.
Johansson LO; Nolan MM; Taniuchi M; Fischer SE; Wickline SA; Lorenz CH
J Cardiovasc Magn Reson; 1999; 1(2):139-43. PubMed ID: 11550346
[TBL] [Abstract][Full Text] [Related]
10. Basic physics of MR contrast agents and maximization of image contrast.
Hendrick RE; Haacke EM
J Magn Reson Imaging; 1993; 3(1):137-48. PubMed ID: 8428081
[TBL] [Abstract][Full Text] [Related]
11. First-pass myocardial perfusion MR imaging with outer-volume suppression and the intravascular contrast agent NC100150 injection: preliminary results in eight patients.
Bjerner T; Johansson L; Ericsson A; Wikström G; Hemmingsson A; Ahlström H
Radiology; 2001 Dec; 221(3):822-6. PubMed ID: 11719685
[TBL] [Abstract][Full Text] [Related]
12. MR image-guided endovascular procedures with the ultrasmall superparamagnetic iron oxide SH U 555 C as an intravascular contrast agent: study in pigs.
Wacker FK; Reither K; Ebert W; Wendt M; Lewin JS; Wolf KJ
Radiology; 2003 Feb; 226(2):459-64. PubMed ID: 12563140
[TBL] [Abstract][Full Text] [Related]
13. MR venography using an intravascular contrast agent: results from a multicenter phase 2 study of dosage.
Larsson EM; Sundén P; Olsson CG; Debatin J; Duerinckx AJ; Baum R; Hahn D; Ebner F
AJR Am J Roentgenol; 2003 Jan; 180(1):227-32. PubMed ID: 12490510
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two blood pool contrast agents for 0.5-T MR angiography: experimental study in rabbits.
Clarke SE; Weinmann HJ; Dai E; Lucas AR; Rutt BK
Radiology; 2000 Mar; 214(3):787-94. PubMed ID: 10715047
[TBL] [Abstract][Full Text] [Related]
15. [Splenosis: value of MRI with injection of a superparamagnetic contrast agent].
Roussel A; Petit E; Mallet L; Zins M
J Radiol; 2008 Dec; 89(12):1944-6. PubMed ID: 19106854
[No Abstract] [Full Text] [Related]
16. Deep venous thrombosis and consecutive pulmonary embolism as the first sign of an ovarian cancer: MR angiography using an intravascular contrast agent (CLARISCAN).
Sandstede JJ; Krause U; Pabst T; Hoffmann V; Braun H; Kenn W; Hahn D
J Magn Reson Imaging; 2000 Sep; 12(3):497-500. PubMed ID: 10992318
[TBL] [Abstract][Full Text] [Related]
17. Breath-hold 3D MR coronary angiography with a new intravascular contrast agent (feruglose)--first clinical experiences.
Sandstede JJ; Pabst T; Wacker C; Wiesmann F; Hoffmann V; Beer M; Kenn W; Bauer W; Hahn D
Magn Reson Imaging; 2001 Feb; 19(2):201-5. PubMed ID: 11358658
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary hemorrhage: imaging with a new magnetic resonance blood pool agent in conjunction with breathheld three-dimensional magnetic resonance angiography.
Weishaupt D; Hilfiker PR; Schmidt M; Debatin JF
Cardiovasc Intervent Radiol; 1999; 22(4):321-5. PubMed ID: 10415223
[TBL] [Abstract][Full Text] [Related]
19. The use of AMI-227 as an oral contrast agent for magnetic resonance imaging.
Rogers J; Lewis J; Josephson L
Invest Radiol; 1994 Jun; 29 Suppl 2():S81-2. PubMed ID: 7928278
[No Abstract] [Full Text] [Related]
20. NC 100150. (Clariscan, PEG-Ferron).
Drugs R D; 2002; 3(5):303-4. PubMed ID: 12455149
[No Abstract] [Full Text] [Related]
[Next] [New Search]
